CVC and GBL Launch €10.7B Bid to Take Recordati Private
Milan, Italy, May 22, 2026 A consortium led by CVC Capital Partners IX and Groupe Bruxelles Lambert (GBL) has...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
Milan, Italy, May 22, 2026 A consortium led by CVC Capital Partners IX and Groupe Bruxelles Lambert (GBL) has...
FOSTER CITY, Calif., April 17, 2026 Gilead Sciences, Inc. has announced that it has obtained all required regulatory approvals...
LAKE FOREST, Ill., April 8, 2026 Assertio Holdings, Inc. has entered into a definitive agreement to be acquired by...
MILAN, Italy, March 26, 2026 Recordati S.p.A. has confirmed receiving a non-binding indication of interest from CVC Capital Partners...
Lexington, Massachusetts — November 19, 2025 — Keros Therapeutics, Inc. has released the preliminary results of its cash tender...
